Skip to main content

Table 4 Number (%) of Ineligible Patients Based on Trials Exclusion Criteria*

From: Eligibility of patients with advanced non-small cell lung cancer for phase III chemotherapy trials

  E1594 SWOG 9509
  Prospective Data
N = 100 (%)
Retro-spective Data
N = 85 (%)
Entire Cohort
N = 185 (%)
Prospective Data
N = 100 (%)
Retro-spective Data
N = 85 (%)
Entire Cohort
N = 185 (%)
Performance Status 37 (37%) 35 (41%) 72 (39%) 37 (37%) 35 (41%) 72 (39%)
Co-morbidities 19 (19%) 31 (36%) 50 (27%) 34 (34%) 41 (48%) 75 (40%)
Previous History of Cancer 12 (12%) 9 (11%) 21 (11%) 12 (12%) 9 (10.5%) 21 (11%)
Brain Metastases 14 (14%) 1 (1%) 15 (8%) 14 (14%) 1 (1%) 15 (8%)
Non Evaluable or Non Measurable Disease 9 (9%) 1 (1%) 10 (5%) 9 (9%) 1 (1%) 10 (5%)
Abnormal Blood Parameter 2 (2%) 6 (7%) 8 (4%) 2 (2%) 7 (8%) 9 (5%)
Previous Chemotherapy 2 (2%) 10 (12%) 12 (6.5%) 2 (2%) 10 (12%) 12 (6.5%)
Unable to give Informed Consent 1 (1%) 3 (3.5%) 4 (2%) 1 (1%) 3 (3.5%) 4 (2%)
  1. * Does not equal 100% due to many patients being excluded on more than one criterion – see Table 3